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Abstract
Background: CXCL14 is a chemoattractant for macrophages and immature dendritic cells. We recently reported that
CXCL14-deficient (CXCL14
2/2) female mice in the mixed background are protected from obesity-induced hyperglycemia and
insulin resistance. The decreased macrophage infiltration into visceral adipose tissues and the increased insulin sensitivity of
skeletal muscle contributed to these phenotypes.
Methodology/Principal Findings:In this study, weperformed a comprehensivestudy for the body weight control of CXCL14
2/2
mice in the C57BL/6 background. We show that both male and female CXCL14
2/2 mice have a 7–11% lower body weight
compared to CXCL14
+/2 and CXCL14
+/+ mice in adulthood. This is mainly caused by decreased food intake, and not by increased
energy expenditure or locomotor activity. Reduced body weight resulting from the CXCL14 deficiency was more pronounced in
double mutant CXCL14
2/2ob/ob and CXCL14
2/2A
y mice. In the case of CXCL14
2/2A
y mice, oxygen consumption was increased
compared to CXCL14
+/2A
y mice, in addition to the reduced food intake. In CXCL14
2/2 mice, fasting-induced up-regulation of Npy
and Agrp mRNAs in the hypothalamus was blunted. As intracerebroventricular injection of recombinant CXCL14 did not change
the food intake of CXCL14
2/2 mice, CXCL14 could indirectly regulate appetite. Intriguingly, the food intake of CXCL14
2/2 mice
was significantly repressed when mice were transferred to a novel environment.
Conclusions/Significance: We demonstrated that CXCL14 is involved in the body weight control leading to the fully obese
phenotype in leptin-deficient or A
y mutant mice. In addition, we obtained evidence indicating that CXCL14 may play an
important role in central nervous system regulation of feeding behavior.
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Introduction
Obesity is caused by increased caloric intake and decreased
energy expenditure. Many secretory peptides and hormones are
involved in the metabolic pathways that regulate feeding behavior
and energy homeostasis. The hypothalamus and brainstem
integrate satietyand hungersignals elicitedby peripheralregulators,
such as leptin and centrally produced orexigenic molecules such as
neuropeptide Y (NPY) and agouti-related protein (AgRP) [1,2].
CXCL14 (also known as BRAK) is a member of the CXC
chemokine family [3,4]. CXCL14 exhibits chemotactic activity
for macrophages, dendritic precursor cells, and natural killer
cells. A CXCL14 receptor has not yet been identified. Although
CXCL14-deficient (CXCL14
2/2) mice do not display severe
defects in their immune systems [5], we recently found that
CXCL14
2/2 female mice weigh significantly less than wild-type
mice and are protected from obesity-induced hyperglycemia,
hyperinsulinemia, hypoadiponectinemia, and insulin resistance
[6]. Expression of CXCL14 is upregulated in adipose tissue and
skeletal muscle in obese mice. Detailed characterization of high
fat diet-fed CXCL14
2/2 female mice revealed that CXCL14
regulates glucose metabolism in two ways: through recruitment
of macrophages to visceral white adipose tissue, and through
partial inhibition of insulin signaling pathways in skeletal muscle.
It is of note that the blood insulin levels of CXCL14
2/2 female
mice are lower than those of control female mice irrespective of
obesity. However, the molecular basis of the gender-specific
phenotype of CXCL14
2/2 mice has not yet been determined.
Although CXCL14 is abundantly expressed in the brain, its
physiological role remains unclear. Major metabolic regulators
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in both skeletal muscle and the hypothalamus in the regulation of
energy metabolism. Therefore, we hypothesized that CXCL14
might also play a role in the control of appetite and/or energy
expenditure through the central nervous system. In this study, we
present evidence that CXCL14 indirectly regulates food intake
and is required for body weight gain in two genetic mouse models
of obesity, ob/ob and A
y mice. In addition, we demonstrate that
CXCL14-deficient mice take a longer time to adapt to a new
environment before initiating feeding behavior.
Results
Characterization of CXCL14
2/2 mice
We have previously reported that female CXCL14
2/2 mice
have lower body weight than CXCL14
+/2 mice on a C57BL/6-
CBA mixed background [6]. To elucidate the cause of this body
weight phenotype, we backcrossed CXCL14
+/2 mice with C57BL/
6 mice for more than 10 generations. Unexpectedly, the birth rate
of CXCL14
2/2 mice from heterozygous pairs was approximately
half of the expected Mendelian ratio for both male and female
offspring (Table 1). CXCL14
2/2 male mice were fertile. In
contrast, CXCL14
2/2 female mice became pregnant, but in most
cases they failed to deliver or nurse the newborn pups (Table 2).
CXCL14
2/2 mice were not easily bred, even by crossing
CXCL14
+/2 dams with CXCL14
2/2 male mice (Table 1). Since
CXCL14
2/2 mice were successfully produced by in vitro fertiliza-
tion of CXCL14
2/2 eggs with CXCL14
2/2 sperm, the lower birth
rate of CXCL14
2/2 mice could be caused by perinatal selection
rather than developmental defects. In fact, there was a tendency
for single litters from CXCL14
2/2 males x CXCL14
+/2 dams to
either have zero or more than 3 null pups. Thus, CXCL14
2/2
pups might be weaker than heterozygous pups and may be out-
competed by their littermates.
CXCL14
2/2 mice exhibit lower body weights
We compared the growth curves of CXCL14
2/2 mice with those
of CXCL14
+/2 and CXCL14
+/+ mice in the C57BL/6 background
between 6 weeks and 26 weeks of age. Among both males and
females, the body weights of CXCL14
2/2 mice were 7–11% lower
than those of their heterozygous and wild-type littermates
(Figure 1A, B). Mean body weight of 3-week-old female
CXCL14
2/2 mice (6.660.26 g) was significantly lower than that
of female CXCL14
+/2 littermates (7.960.34 g; n=5, P=0.0479),
indicatingthat the lighterbodyweightofCXCL14
2/2 mice emerges
at the weaning period. As the metabolism-related phenotypes of
CXCL14
2/2 mice were more prominent in females in initial
experiments, subsequent experiments were carried out using female
CXCL14
2/2 mice and CXCL14
+/2 littermates.
We next generated double mutant mice by crossing
CXCL14
2/2 and leptin-deficient ob/ob mice (CXCL14
2/2ob/
ob), and compared their growth with CXCL14
+/2ob/ob mice.
CXCL14 deficiency resulted in a 14–39% lower body weight
in ob/ob mice (Figure 1C). This was also the case when we
crossed CXCL14
2/2 with another obese mutant mouse model,
A
y, in which agouti protein is ectopically overexpressed in the
hypothalamus. CXCL14
2/2A
y mice were significantly lighter
than CXCL14
+/2A
y mice (Figure 1D). Moreover, this finding
was reproduced in KKA
y mice, a more hyperphagic A
y mouse
strain (Figure 1E). Taken together, these data show that the
lower body weight resulting from CXCL14 deficiency moder-
ates obesity caused by genetic hyperphagia and reduced energy
expenditure. We thus presume that the point of action of
CXCL14 is genetically downstream or independent of the ob/
ob and A
y mutations.
To examine whether growth retardation contributes to the
body weight phenotype of CXCL14
2/2 mice, we compared
concentrations of growth hormone and IGF-I in the circulation
of CXCL14
2/2 and CXCL14
+/2 mice, and of CXCL14
2/2ob/ob
and CXCL14
+/2ob/ob mice. We found no significant difference
in either comparison (Figure 2A–D). As previously reported
[7], reduced growth hormone levels associated with the ob/ob
mutation were observed in CXCL14
2/2ob/ob mice when they
were compared to CXCL14
2/2 mice (Figure 2A, B). However,
the serum growth hormone concentrations of CXCL14
2/2ob/
ob mice were indistinguishable from those of CXCL14
+/2ob/ob
mice, ruling out the involvement of the growth hormone/IGF-
I axis in the lighter body weight phenotype of CXCL14
2/2
mice. Mean nose-anus length of CXCL14
2/2 mice was nearly
identical to that of CXCL14
+/2 mice (Figure 2E). In contrast,
however, mean nasal-anal length of CXCL14
2/2ob/ob mice
was significantly shorter than CXCL14
+/2ob/ob mice
(Figure 2F). As we have previously reported the shorter nose-
anus length of CXCL14
2/2 mice fed a high fat diet [6],
CXCL14 could be involved in the body length regulation
under the obese conditions.
Table 1. Birth rate and fertility of CXCL14
2/2 mice.
Genotypes of F1 mice from (+/2)m a l ex( +/2) female
crosses
(+/+)( +/2)( 2/2) Total
Male 31 54 12 (12.4%*) 97
Female 27 35 10 (13.9%*) 72
Total 58 89 22 (13%*) 169
Genotypes of F1 mice from (2/2) male x (+/2) female
crosses
(+/2)( 2/2) Total
Male 115 44 (27.7%**) 159
Female 89 37 (29.4%**) 126
Total 204 81 (28.4%**) 285
Parturition of pregnant (2/2) females
Failure Dead pups Success Total
4921 5
Expected birth ratios are 25% (*) and 50% (**), respectively.
doi:10.1371/journal.pone.0010321.t001
Table 2. Primers for RT-PCR analysis used in this study.
Gene Forward primer (59-39) Reverse primer (59-39)
Size
(bp)
CXCL14 CCAAGATTCGCTATAGCGAC CCTGCGCTTCTCGTTCCAGG 191
Npy CTCCGCTCTGCGACACTACA AATCAGTGTCTCAGGGCTGGA 75
Agrp GCGGAGGTGCTAGATCCACA AGGACTCGTGCAGCCTTACAC 69
Pomc ACCTCACCACGGAGAGCAAC GCGAGAGGTCGAGTTTGCA 59
Socs3 CCTTTGACAAGCGGACTCTC GCCAGCATAAAAACCCTTCA 215
Cart CGAGAAGAAGTACGGCCAAG GGAATATGGGAACCGAAGGT 132
GAPDH AAATTCAACGGCACAGTCAA GAACGGACGGAGATGATGAC 218
doi:10.1371/journal.pone.0010321.t002
CXCL14 Controls Body Weight
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weight in CXCL14
2/2 mice
To determine whether the lower body weight of CXCL14
2/2 mice
was due to reduced food intake or increased energy expenditure, we
measured the daily food intake of CXCL14
+/2 and CXCL14
2/2 mice
from 8–12 weeks of age, and CXCL14
+/2A
yand CXCL14
2/2A
ymice
from 12–16 weeks of age. CXCL14
2/2 mice ate 6–7% less food than
CXCL14
+/2 mice (Fig. 3A), whereas CXCL14
2/2A
y mice ate 14%
less than CXCL14
+/2A
y mice (Figure 3B). However, oxygen
consumption and locomotor activity were not significantly different
between CXCL14
+/2 and CXCL14
2/2 mice either at night or during
the daytime (Figure 3C, E). In CXCL14
2/2A
y mice, oxygen
consumption was increased compared to CXCL14
+/2A
y mice
(Figure 3D). We did not detect any significant difference in locomotor
activity between CXCL14
+/2A
y and CXCL14
2/2A
y mice (Figure 3F).
T h e s ed a t as u g g e s tt h a tar e d u c t i o ni nf o o di n t a k ei sam a j o rc a u s eo f
the lower body weight of CXCL14
2/2 mice. In addition, enhanced
energy expenditure could contribute in part to the lower body weight
of CXCL14
2/2A
y mice. Core body temperature was not significantly
changed by CXCL14 deficiency in either normal or A
y mice
(Figure 4A, B).
Expression of appetite regulators in CXCL14-deficient
mice
We next examined mRNA expression of appetite-regulating
peptides in the hypothalamus using real-time RT-PCR. Under the
ad libitum condition of a standard diet, expression levels of Npy,
Agrp, Proopiomelanocortin (Pomc), Socs3, and Cocaine and amphetamine-
regulated transcript (Cart) were comparable between CXCL14
+/+ and
CXCL14
2/2 mice (Figure 5), and between CXCL14
+/2A
y and
CXCL14
2/2A
y mice (data not shown). However, fasting-induced
up-regulation of Npy and Agrp mRNAs was observed, but
significantly blunted in the hypothalami of CXCL14
2/2 mice
compared to control CXCL14
+/+ mice (Figure 5). In contrast,
mRNA level of Socs3 was lowered in the hypothalami of fasted
CXCL14
2/2 mice as similar as fasted control mice (Figure 5),
implying that a critical downstream regulator of the leptin-
mediated anorexigenic signaling pathway is not severely affected
in CXCL14
2/2 mice. There was no difference in the expressions of
Pomc and Cart between two groups under the fasted condition
(Figure 5).
Effect of intracerebroventricular (ICV) or intraperitoneal
(IP) administration of CXCL14 to the food intake of
CXCL14
2/2 mice
To determine whether CXCL14 acts directly on appetite-
regulating neurons, we first injected recombinant CXCL14 into
the cerebroventricular cavity of CXCL14
2/2 mice. The biological
activity of CXCL14 was verified using a chemotaxis assay (data
not shown). We used age- and sex-matched CXCL14
+/+ mice as
controls. This experiment was made more difficult by the fact that
CXCL14
2/2 mice showed severe anorexia after the first ICV
Figure 1. Lower body weights in CXCL14
2/2 mice and CXCL14
2/2 crosses with obese mutant mice. Body weight change of male CXCL14
+/+
(n=12), CXCL14
+/2 (n=76) and CXCL14
2/2 mice (n=37) (A); female CXCL14
+/+ (n=13), CXCL14
+/2 (n=38) and CXCL14
2/2 (n=19) mice (B); female
CXCL14
+/2ob/ob (n=9) and CXCL14
2/2ob/ob (n=4) mice (C); female CXCL14
+/2A
y (n=11) and CXCL14
2/2A
y (n=5) mice (D); and female CXCL14
+/+KKA
y
(n=4), CXCL14
+/2KKA
y (n=13) and CXCL14
2/2KKA
y mice (n=5) (E), are shown. Each data point represents the mean 6 SEM. *, P,0.05; **, P,0.01; n.s.,
not significant compared to the corresponding value for CXCL14
+/2, CXCL14
+/2ob/ob, CXCL14
+/2A
y,o rCXCL14
+/2KKA
y control mice.
doi:10.1371/journal.pone.0010321.g001
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This phenomenon was not observed in CXCL14
+/+ mice. After a
3-week interval, we performed a second and third set of
experiments in which CXCL14
2/2 mice were adapted to this
experimental procedure such that they returned to normal feeding.
In both CXCL14
+/+ and CXCL14
2/2 mice, ICV injection of
CXCL14 did not significantly increase food intake (Figure 6A, B).
Next we performed IP injection of recombinant CXCL14 into
CXCL14
2/2 mice to understand the systemic effect of CXCL14.
Mice were injected with PBS for two days before CXCL14
administration to be habituated to the procedure. IP injection of
CXCL14 into control CXCL14
+/+ mice did not significantly affect
their food intake (Figure 7A). Unexpectedly, however, CXCL14
2/2
mice ate a lesser amount of food during a day just after the IP
injection of CXCL14 when compared to PBS-injected controls
(Figure 7B). This effect was transient, as food intake of CXCL14-
injected CXCL14
2/2 mice was returned to normal levels on the
second day. Serum concentrations of CXCL14 in age/sex-matched
mice injected with CXCL14 (2 mg/g body weight) were 90 ng/ml
in average (n=3) at 1 hour after injection and became under the
detection level (,2.5 ng/ml) at 3 hours after injection, indicating a
rapid degradation of recombinant CXCL14 in vivo.
The feeding behavior of CXCL14
2/2 mice is sensitive to
environmental changes
To obtain further insights into the feeding behavior of
CXCL14
2/2 mice, we individually transferred CXCL14
+/+ and
CXCL14
2/2 mice from their regular home cages to a locomotor
behavior monitoring cage without any habituation. The food
intake of CXCL14
2/2 mice was severely repressed during the first
night when compared to wild-type mice, but it gradually recovered
to normal levels over the next 3 days (Figure 8A, B). In contrast,
Figure 2. Comparison of growth hormone/IGF-1 levels and nose-anus lengths between CXCL14
+/2 and CXCL14
2/2 female mice. (A, B)
Daytime concentrations of serum growth hormone in 6-week-old female CXCL14
+/2 (n=10) and CXCL14
2/2 mice (n=9) (A), and 12-week-old female
CXCL14
+/2ob/ob (n=4) and CXCL14
2/2ob/ob (n=4) mice (B). (C, D) Daytime concentrations of serum IGF-1 in 6-week-old female CXCL14
+/2 (n=8) and
CXCL14
2/2mice(n=8)(C),and12-week-oldfemaleCXCL14
+/2ob/ob(n=4)andCXCL14
2/2ob/ob(n=4)mice(D).(E,F)Themeannasal-anallengthsof15-
week-old female CXCL14
+/+ (n=6) and CXCL14
2/2mice (n=6) (E), and 6-month-old female CXCL14
+/2ob/ob (n=4) and CXCL14
2/2ob/ob (n=10) mice (F).
Each data point represents the mean 6 SEM. **, P,0.01; n.s., not significant compared to the corresponding value for CXCL14
+/2 or CXCL14
+/+ control
mice.
doi:10.1371/journal.pone.0010321.g002
CXCL14 Controls Body Weight
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habituated CXCL14
+/+ and CXCL14
2/2 mice (Figure 8C, D).
These data clearly indicate that CXCL14 is required for normal
adaptation to a novel environment and initiation of feeding
behavior. As the food intake of CXCL14
2/2 mice in their home
cages was constant even after transferring them to fresh cages, the
lower body weights seen in CXCL14
2/2 mice were not due to
delayed adaptation to routine cage changes.
Discussion
Although CXCL14 is known to be a chemoattractant for
macrophages and immature dendritic cells, CXCL14-deficient
mice exhibit unexpected phenotypes: lower body weight and a
reduced birth rate. In this study, we explored the underlying
mechanisms of the former phenotype. A major cause of the lower
body weight of CXCL14
2/2 mice is lower food intake, but not
increased energy expenditure. Since weaned CXCL14
2/2 mice
were already lighter than CXCL14
+/2 littermates, reduced
capacity of food intake in CXCL14
2/2 mice should be established
during the postnatal three weeks, thereby gaining body weight in
proportion to keep the slightly lighter phenotype over the life time.
The lighter body weight phenotype was more prominent in two
representative hyperphagic mutant mouse strains, ob/ob and A
y.
The daily food intake of CXCL14
2/2A
y mice was approximately
86% of that of CXCL14
+/2A
y mice. In addition, the basal energy
expenditure of CXCL14
2/2A
y mice was significantly higher than
that of CXCL14
+/2A
y mice. These two properties protected
CXCL14
2/2A
y mice from being obese. It is known that in AgRP/
NPY neurons in the hypothalamus, agouti protein antagonizes
melanocortin-4 receptors [8], which act to decrease appetite and
increase energy expenditure. Intriguingly, we found that decreased
expression of Npy and Agrp mRNAs in the hypothalami of fasted
CXCL14
2/2 mice when compared to fasted control mice. Hence,
in CXCL14
2/2 mice, a signal transduction pathway for the fasting-
induced up-regulation of Npy/Agrp genes could be partially
impaired. Alternatively, it is possible that AgRP/NPY neurons
themselves are reduced in CXCL14
2/2 mice. Further investiga-
tions are necessary to distinguish above possibilities and uncover
the roles of CXCL14 in the hypothalamus.
The ICV injection of CXCL14 did not stimulate food intake in
CXCL14
+/+ mice or CXCL14
2/2 mice, suggesting that CXCL14 is
not a typical orexigenic hormone. However, the finding of
attenuated induction of Npy and Agrp mRNAs in the hypothalami
of fasted CXCL14
2/2 mice supports the idea that CXCL14
modulates the expression of appetite-regulators. At this moment,
we do not know the reason why food intake of CXCL14
2/2 mice
was repressed by the IP injection of CXCL14. Since CXCL14 is
inhibitory for the insulin-mediated glucose uptake in skeletal muscle
and the serum insulinconcentrations of CXCL14
2/2 miceare lower
than those of CXCL14
+/2 mice [6], temporal increase of blood
glucose levels might contribute to the observed phenomenon.
In this study, we revealed the possibility that CXCL14
2/2 mice are
more sensitive to novelty-induced stress. Feeding behavior can be
Figure 3. Comparison of food intake, energy expenditure, and locomotor activity between CXCL14
+/2 and CXCL14
2/2 female mice.
(A, B) Daily food intake of female CXCL14
+/2 (n=8) and CXCL14
2/2 (n=7) mice (A), and female CXCL14
+/2A
y (n=8) and CXCL14
2/2A
y (n=4) mice (B).
(C–F) Oxygen consumption of female CXCL14
+/2 (n=6) and CXCL14
2/2 (n=6) mice (C), and female CXCL14
+/2A
y (n=6) and CXCL14
2/2A
y (n=3) mice
(D), and locomotor activity of female CXCL14
+/2 (n=4) and CXCL14
2/2 (n=6) mice (E), and female CXCL14
+/2A
y (n=8) and CXCL14
2/2A
y (n=5) mice
(F) during night- and daytime are shown. Sixteen to 20 week-old mice were used for these experiments. Each data point represents the mean 6 SEM.
*, P,0.05; **, P,0.01; n.s., not significant compared to the corresponding value for CXCL14
+/2 control mice.
doi:10.1371/journal.pone.0010321.g003
CXCL14 Controls Body Weight
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CXCL14 mRNA is most abundantly expressed in the cortex,
hippocampus and cerebellum (http://www.brain-map.org provided
by the Allen Institute for Brain Science). Among appetite-related
regions, paraventricular hypothalamus, suprachiasmatic nucleus and
piriform cortex show a relatively stronger expression of CXCL14
mRNA. Expression levels of CXCL14 in the arcuate nucleus and
ventromedialnucleusofthe hypothalamusare low. We confirmed the
expression of CXCL14 mRNA in the cortex, hippocampus and
hypothalamus of adult mice by RT-PCR (YN, SO, YM, TH,
unpublished data). As CXCL14 is present not only in the
hypothalamus, but also in the cortex and hippocampus, we speculate
that CXCL14 may be required for the establishment of neural
circuits that are closely linked with feeding behavior. Consistent with
this, the feeding behavior of CXCL14
2/2 mice was repressed on the
first night after they were transferred to a novel environment.
However, the locomotor activity of the mutant mice was not
significantly different during this time; thus, it is unlikely that the
novelty feeding-suppression phenotype of CXCL14
2/2 mice is a
result of fear. This trait may be related to impairment of anti-
depressive functions in the brain. It has been previouslydemonstrated
that novelty-suppressed feeding is directly associated with serotoner-
gic neurons in the dentate gyrus [9], which are established during the
first 3 weeks after birth [10]. We plan to subject CXCL14
2/2 mice to
a pathological diagnosis of the brain as well as a battery of behavioral
tests, including the novelty-suppressed feeding test.
We have previously reported that female, but not male,
CXCL14
2/2 mice show amelioration of obesity-induced insulin
resistance [6]. In female CXCL14
2/2 mice on the C57BL/6
genetic background, serum insulin concentrations were signifi-
cantly lower than those of CXCL14
+/2 female mice (TH,
unpublished data). This phenotype was not observed in male
CXCL14
2/2 mice. In contrast, in the present study, we show that
the reduced birth rate and lower body weight of CXCL14
2/2 mice
are seen in both males and females. During the ICV injection
experiments, we noticed that female CXCL14
2/2 mice were not as
aggressive as wild-type mice. This tendency was also observed in
male CXCL14
2/2 mice. Therefore, the behavioral differences seen
in CXCL14
2/2 mice are not gender-specific, which is in sharp
contrast to the metabolic phenotypes of CXCL14
2/2 mice.
Among CC and CXC chemokine family members, only
CXCL14 and CXCL12 are well conserved from fish to humans
[11]. Only two amino acid residues of CXCL14 are different
between mice and humans. Both of these chemokines are
abundantly expressed in the brain. CXCL12 has been shown to
be essential for neurogenesis in the fetus through recruitment of
neuronal precursor cells [12–14]. In this study, we have provided
the first evidence for neuronal defects in CXCL14-deficient mice.
They do not appearto be global, butrathermorespecificallyrelated
to novelty-associated feeding behavior. Considering the fact that the
peripheralfunctions of CXCL14arepro-diabetic,CXCL14maybe
an important metabolic regulator for the maintenance of energy
stores. As CXCL14 may function in multiple regions of the brain, it
is important to determine how its functions in various brain regions
are coordinated to regulate feeding behavior.
Finally, here we presented evidence demonstrating that
disruption of CXCL14 results in reduced body weight using two
representative genetic mouse models of obesity. CXCL14-deficien-
cy resulted in repression of feeding behavior in a novel
environment without affecting locomotor activity. Therefore,
CXCL14 in the central nervous system could be a potential
target for anti-hyperphagic therapy. We are making efforts to
identify CXCL14 receptors and to establish sensitive bioassay
systems for future therapeutic applications.
Materials and Methods
Animal experiments
CXCL14
+/2 mice were backcrossed with C57BL/6 mice (Nihon
SLC, Hamamatsu, Japan) for more than 10 generations and
intercrossed with each other to obtain CXCL14
+/+, CXCL14
+/2
and CXCL14
2/2 littermates. For some experiments, CXCL14
2/2
male and CXCL14
+/2 female mice were crossed to produce
CXCL14
+/2 and CXCL14
2/2 mice. Mice were fed a standard diet
(CE-2) (Nihon CLEA, Tokyo, Japan). KKA
y (mixed background)
and ob/+ mice (C57BL/6 background) were purchased from
Nihon CLEA and Charles River (Yokohama, Japan), respectively.
A
y mice (C57BL/6 background) were imported from The Jackson
Laboratory (Bar Harbor, ME). All mice were maintained under a
12-hour light, 12-hour dark cycle in a pathogen-free animal
facility. All experimental procedures involving mice were pre-
approved by Ethical committee of Animal Experiments in The
Tokyo Metropolitan Institute of Medical Science, and performed
according to the guidelines for Proper Conduct of Animal
Experiments (http://www.scj.go/en/animal/index.html).
Figure 4. Body temperature is not affected by CXCL14
deficiency. Core body temperatures of female CXCL14
+/2 (n=6) and
CXCL14
2/2 (n=6) mice (A), and female CXCL14
+/2A
y (n=6) and
CXCL14
2/2A
y (n=3) mice (B). Eighteen to 22 week-old mice were used.
Each data point represents the mean 6 SEM. n.s., not significant
compared to the corresponding value for CXCL14
+/2 control mice.
doi:10.1371/journal.pone.0010321.g004
CXCL14 Controls Body Weight
PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e10321Figure 5. CXCL14 deficiency attenuates fasting-induced up-regulation of Npy and Agrp mRNAs in the hypothalamus. Relative mRNA
expression levels of appetite-regulating molecules (Npy, Agrp, Pomc, Socs3 and Cart) in the hypothalami of female CXCL14
+/+ and CXCL14
2/2 mice.
Eighteen to 22 week-old mice were used. GAPDH was used as the normalization control. Each data point represents the mean 6 SEM (n=3).
*, P,0.05; **, P,0.01; n.s., not significant compared to the corresponding value for CXCL14
+/+ control mice.
doi:10.1371/journal.pone.0010321.g005
Figure 6. Effects of ICV injection of CXCL14 protein in CXCL14
+/+
and CXCL14
2/2 mice. Female CXCL14
+/+ mice (WT, n=6) (A) and
CXCL14
2/2 mice (KO, n=5) (B) were subjected to ICV injection of
recombinant CXCL14 or PBS. Daily food intake measurements before
and after the ICV injection in a single experiment are separately shown.
Sixteen to 20 week-old mice were used for this experiment. Each data
point represents the mean 6 SEM. None of the data points for CXCL14-
injected samples were statistically significant from the corresponding
values for the PBS injection control.
doi:10.1371/journal.pone.0010321.g006
Figure 7. Effects of IP injection of CXCL14 protein in CXCL14
+/+
and CXCL14
2/2 mice. Female CXCL14
+/+ mice (WT, n=4) (A) and
CXCL14
2/2 mice (KO, n=4) (B) were intraperitoneally injected with
recombinant CXCL14 or PBS. To habituate mice to the IP injection, all
mice were intraperitoneally injected with PBS at indicated time points
(shaded arrowheads) before CXCL14 injection (open arrowheads). Daily
food intake measurements before and after injection in a single
experiment are separately shown. Twelve to 14 week-old mice were
used for this experiment. Each data point represents the mean 6 SEM.
*, P,0.05 compared to the PBS control. Except for one point, all other
data points were statistically insignificant from the corresponding
values for the PBS injection controls.
doi:10.1371/journal.pone.0010321.g007
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Serum concentrations of growth hormone and IGF-I were
determined using ELISA kits from Shibayagi (Shibukawa, Gumma,
Japan) and R&D Systems (Minneapolis, MN), respectively. Mouse
core body temperaturewasmeasuredusingan electricthermometer
with a probe (Muromachi Kikai, Tokyo, Japan).
Oxygen consumption and locomotor activity
Oxygen consumption of female mice was measured using an O2/
CO2 metabolism measurement system (MK-5000, Muromachi Kikai)
under the fasting condition. Spontaneous locomotor activity and food
intake of mice were recorded using a laboratory animal monitoring
system (ACTIMO/MFD-100, Shinfactory, Fukuoka, Japan).
Quantitative RT-PCR
Total RNA was reverse-transcribed using High Capacity RNA-
to-cDNA Master Mix (Applied Biosystems, Foster City, CA). Real-
time PCR was performed with SYBR premix Ex Taq II (Takara,
Otsu, Japan) using a LightCycler480 system (Roche Applied
Science, Indianapolis, IN). Messenger RNA expression levels were
determined using Relative Quantification Software with Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) as an internal control.
Primer sequences are listed in Table 2.
ICV and IP injection
For ICV injection, female mice were anesthetized with xylazine
(10 mg/Kg) plus ketamine (100 mg/Kg) and placed in a Kopf
stereotaxic frame (Koft Instruments, Tujunga, CA). Then a
chronic double-walled stainless steel cannula was stereotaxically
implanted into the lateral ventricle of each mouse according to the
atlas book [G. Paxinos & K. B. J. Franklin: The Mouse Brain in
Stereotaxic Coordinates, Second edition (Academic Press, Inc., San
Diego, 1997)]. The stereotaxic coordinates for the lateral ventricle
were AP 0.2 (0.2 mm posterior to bregma), L 1 (1 mm left from
mid-sagittal line) and H 2.4 (2.4 mm below bregma). Two weeks
after the surgery, unanesthetized mice were injected with 2 ml
(2 mg) of 100 nM human CXCL14 (PeproTech, Rocky Hill, NJ) in
PBS or PBS over 1 minute via an inner cannula using a Hamilton
syringe. ICV injections were performed less than 1 hour before
beginning of the dark period. All mice were handled daily to
habituate them to experimental maneuvers.
IP injection was carried out without anesthesia just before
beginning of the dark period. After two-day adaptation with PBS
injections, mice were intraperitoneally injected with 200 mlo f
human CXCL14 in PBS at 2 mg/g body weight or PBS with a
26G syringe. Serum concentrations of CXCL14 in mice were
determined by using DY866 DuoSet ELISA kit (R&D Systems).
Statistical analysis
All statistical analysis was performed using ANOVA repeated
measures analysis (Statview J5.0, Abacus Concepts). Between factors
related to the breeding and feeding conditions in home cages were
regarded to be identical among different mouse strains. A P-value of
,0.05 was considered significant for the unpaired Student’s t-test.
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Figure 8. Suppressed feeding behavior of CXCL14
2/2 mice in a novel environment. Female mice were transferred to the locomotor activity
monitoring cage without habituation. Food intake (A, B) and locomotor activity (C, D) of CXCL14
+/+ mice (WT, n=3) and CXCL14
2/2 mice (KO, n=3)
during the 3 subsequent night-day cycles are shown. Sixteen to 20 week-old mice were used for this experiment. Each data point represents the
mean 6 SEM. *, P,0.05; n.s., not significant compared to the corresponding value for CXCL14
+/+ control mice.
doi:10.1371/journal.pone.0010321.g008
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